jonah fox

With multi-cancer early detection (MCED) tests gaining increasing media attention and interest from patients, providers, insurers, and reinsurers alike, numerous questions have arisen surrounding these diagnostic tests. This article aims to address many of the frequently asked questions surrounding these relatively new studies and the associated implications for various stakeholders involved. What is a Multi-cancer Early Detection Test? MCED screens for signs of cancer in the blood.

Obesity affects more than 40% of the U.S. adult population1 and represents one of the most significant challenges within our healthcare system today. Overweight and obesity increase the risk of type 2 diabetes, heart disease, hypertension, and dyslipidemia, and are significant drivers of both morbidity and mortality. Glucagon-like peptide‑1 (GLP‑1) receptor agonists represent a powerful treatment option to aid in managing these complex conditions.

An overnight polysomnography is performed in a healthcare facility and utilizes a number of components (e.g., electrocardiogram, electroencephalogram, electrooculogram, electromyography, respiratory rate, tidal volume, and inspiratory and expiratory volumes) in order to calculate an apnea-hypopnea index (AHI). The AHI indicates the number of apneas (when breathing stops during sleep) and hypopneas (reduced breathing with decreased oxygen) per hour of sleep.